Real‐world experience of carfilzomib‐associated cardiovascular adverse events: SEER‐Medicare data set analysis

Carfilzomib was approved for the treatment of multiple myeloma in 2012 and since then there have been concerns for cardiovascular toxicity from its use. With this study, we aim to further study the hazards and underlying risk factors for cardiovascular adverse events associated with carfilzomib. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bishnoi, Rohit, Xie, Zhigang, Shah, Chintan, Bian, Jiang, Murthy, Hemant S., Wingard, John R., Farhadfar, Nosha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826471/
https://www.ncbi.nlm.nih.gov/pubmed/33169938
http://dx.doi.org/10.1002/cam4.3568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826471/
https://www.ncbi.nlm.nih.gov/pubmed/33169938
http://dx.doi.org/10.1002/cam4.3568

Ejemplares similares